Watertown biotech acquired by Novo Nordisk for $1.1B


Two years after raising $277 million in its IPO, a Watertown biotech developing drugs for blood diseases is being acquired by Novo Nordisk.

Previous How Covid, 'industrial logic' and a threat played out in a multibillion-dollar biotech merger
Next Walgreens Boots Alliance adds senior vice president to executive team